Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis

By LabMedica International staff writers
Posted on 13 Aug 2026

Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. More...

Between 20% and 50% of affected patients experience more than one flare, which can be more severe and may persist for months or years after therapy ends. Why the condition develops in some patients and recurs in others remains unclear. New findings demonstrate immune-cell features that may underpin recurrence and suggest potential biomarkers and therapeutic targets.

The University of Texas MD Anderson Cancer Center led a study published in Cancer Immunology Research on July 31, 2026, that characterizes ICI-associated inflammatory arthritis as behaving like an immune‑memory disease. Investigators identified two immune cell populations that were present in both initial and recurrent flares: inflammatory CD8 T cells and a subset of CD4 T cells co‑expressing PD‑1 and CXCL13. 

Researchers analyzed joint fluid from six patients at the time of their first flare and again during a recurrent episode. The persistent presence of the two T‑cell populations indicates reactivation of established inflammatory cells rather than generation of a new response with each flare. During subsequent flares, these cells produced higher levels of inflammatory signaling molecules, regulatory T cells also produced inflammatory mediators, and cytokine networks became more pronounced, pointing to a coordinated inflammatory environment within the joint.

The authors note that it remains unclear why ICI‑related arthritis develops in some patients and not others. The study suggests that the identified immune cell populations could serve as biomarkers to identify patients at higher risk for future flares. The findings also provide a foundation for developing targeted approaches that suppress arthritis while preserving antitumor benefit.

“Cancer immunotherapy works by creating a lasting immune response against tumors, but that same persistence may also contribute to recurring inflammatory side effects that can be debilitating for patients. By identifying the immune cells that drive recurrent arthritis, we can inform treatment strategies that reduce the risk of future flares while preserving the therapy's effectiveness against cancer,” said Roza I. Nurieva, Ph.D., professor of Immunology at The University of Texas MD Anderson Cancer Center.

Related Links
UT MD Anderson Cancer Center 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Manual Pipetting Aid
Pipette Controllers macro
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.